Baseline intratumoral TCRbeta; and TCRgamma; repertoires predict response to immune checkpoint inhibitors in advanced renal cell carcinoma

Résumé fourni par la source

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced renal cell carcinoma (RCC), yet only a subset of patients derives durable clinical benefit and no robust predictive biomarkers have been implemented in routine clinical practice. As T-cell receptor (TCR)-mediated antigen recognition underlies effective antitumor immunity, characterization of the intratumoral TCR repertoire may provide clinically relevant information for patient stratification. Here, we evaluated the predictive value of the baseline intratumoral TCRβ and TCRγ repertoires in a real-world cohort of patients with advanced RCC treated predominantly with first-line immune checkpoint inhibitor-based regimens. Responders exhibited a significantly more even TCRβ repertoire together with increased TCRγ diversity and clonal richness, whereas non-responders showed greater TCRγ clonal dominance. In addition, the preferential usage of specific TRBV genes, including TRBV5.7, TRBV7.1, and TRBV18, was associated with clinical response and longer progression-free survival. In this exploratory cohort, integration of the most informative TCRβ and TCRγ variables into a combined random forest model yielded an area under the receiver operating characteristic curve of 0.90 in leave-one-out cross-validation, with 100% sensitivity and 81.8% specificity at the selected threshold. To our knowledge, this is the first study to simultaneously characterize baseline intratumoral TCRβ and TCRγ repertoires in patients with advanced RCC predominantly receiving first-line immune checkpoint blockade. These findings support baseline intratumoral TCR repertoire features as candidate tissue biomarkers for pretreatment patient stratification and provide a rationale for the prospective validation of TCR repertoire profiling as a predictor of immunotherapy benefit in RCC.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.